Skip to main content
RLYB logo

RLYB · Rallybio Corp

Track RLYB — free
$16.99 +0.03 (+0.18%) At close · Aug 14
Market Cap
$90.23M
Shares
5.31M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.99 Open$17.01 Day$16.67–17.23 Since split$4.33–16.99 Avg vol 30d37K Short int63K · 1.2% float · 2.1d Short vol48% Last earningsMar 13, 2025 DataFeb 2026–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Feb 6, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Feb 6, 2026.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +6%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +209%
trailing
Relative strength +195%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-3% holders QoQ · +10 funds added
Insider flow Accumulating
Net +$142.6K over 90 days · 0% sells
Short interest Falling
1.20% of float · ▼ -62.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Squeeze score 54
elevated · 0–100
Fundamentals
Excellent
Revenue growth +35%
Y/Y
EPS growth +85%
Y/Y
Free cash flow $-29.8M
Valuation P/E 2.1
below peers
Balance sheet $31.4M
net cash
Quant / Vol
risk profile
High
Volatility 108%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+6% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-3% holders QoQ · +10 funds added
Insider flow Accumulating
Net +$142.6K over 90 days · 0% sells
Short interest Falling
1.20% of float · ▼ -62.7% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Price context
position in its range since split · 2026-02-06
Range low $4 Now $17 · 100% Range high $17
vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RLYB
Rallybio Corp
this stock
$90.23M +34.9% 2.1 1.2%
ONC
BeOne Medicines Ltd.
$513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
$52.94B +1.2% 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
37
% held
218.0%
Net QoQ
+6.9M sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Falling
Shares short
63.5K
Days to cover
2.1d
Change
-106.7K sh
View
Short Volume
Short vol %
48%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
6.7K
Value
$105.9K
As of
Jun 26, 2026
View
Off-Exchange
Off-exchange %
29.6%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$142.6K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$858.0K
Net income (FY)
$-9.0M
EPS diluted
$-1.59
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 6, 2026
This year
9
View
Exempt Offerings
Offering
$6.6M
Filed
Apr 22, 2024
View
Earnings & Events
Earnings Calls
Last call
Mar 13, 2025
View

Performance

Raw-price comparisons begin at the captured split on Feb 6, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
RLYB +5.1% +3.5% +208.9% +6.7%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +4.7% -1.0% +195.1% +2.7%
Key facts CIK 1739410 CUSIP 75120L209 13F (30d) 42 filings 40 filers Visit website Investor relations